DK2971045T3 - Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen - Google Patents

Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen Download PDF

Info

Publication number
DK2971045T3
DK2971045T3 DK14776084.7T DK14776084T DK2971045T3 DK 2971045 T3 DK2971045 T3 DK 2971045T3 DK 14776084 T DK14776084 T DK 14776084T DK 2971045 T3 DK2971045 T3 DK 2971045T3
Authority
DK
Denmark
Prior art keywords
recombinant
compositions
methods
tumor antigen
cell receptors
Prior art date
Application number
DK14776084.7T
Other languages
English (en)
Inventor
Kunle Odunsi
Junko Matsuzaki
Takemasa Tsuji
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of DK2971045T3 publication Critical patent/DK2971045T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14776084.7T 2013-03-13 2014-03-13 Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen DK2971045T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778673P 2013-03-13 2013-03-13
PCT/US2014/025673 WO2014160030A2 (en) 2013-03-13 2014-03-13 Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen

Publications (1)

Publication Number Publication Date
DK2971045T3 true DK2971045T3 (da) 2019-09-16

Family

ID=51625624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14776084.7T DK2971045T3 (da) 2013-03-13 2014-03-13 Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen

Country Status (7)

Country Link
US (3) US10000546B2 (da)
EP (2) EP3404111A1 (da)
JP (2) JP6464140B2 (da)
CA (1) CA2906587C (da)
DK (1) DK2971045T3 (da)
ES (1) ES2746240T3 (da)
WO (1) WO2014160030A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404111A1 (en) 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
ES3063691T3 (en) * 2015-09-22 2026-04-20 Univ Wuerzburg J Maximilians A method for high level and stable gene transfer in lymphocytes
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
DK3399985T3 (da) 2016-01-06 2022-03-21 Health Research Inc Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer
SMT202200306T1 (it) 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
GB201617716D0 (en) * 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
WO2018126002A1 (en) * 2016-12-29 2018-07-05 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11702459B2 (en) 2017-03-07 2023-07-18 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
US10255011B2 (en) * 2017-03-10 2019-04-09 Xerox Corporation Methods and systems for applying spot color on one or more pages as specified by a user
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2019067805A1 (en) 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN108103106A (zh) * 2018-01-09 2018-06-01 河南省华隆生物技术有限公司 一种pFTM3GW重组载体及其制备方法和应用
WO2019157279A1 (en) * 2018-02-10 2019-08-15 Berkeley Lights, Inc. Mutant idh1 specific t cell receptor
US11046068B2 (en) 2018-02-26 2021-06-29 Fanatics, Inc. Direct-to-transfer printing system and process, and components and ASR system therefor
TWI822726B (zh) * 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Ｎｙｅｓｏ ｔ細胞受體
US12150973B2 (en) 2018-05-03 2024-11-26 University Of Utah Research Foundation OCA-B peptide conjugates and methods of treatment
EP3807642B1 (en) * 2018-05-11 2024-06-12 Memorial Sloan-Kettering Cancer Center Methods for identifying antigen-specific t cell receptors
EP4252759B1 (en) 2018-05-11 2025-08-06 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
JP7599205B2 (ja) 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
MX2021002125A (es) * 2018-09-12 2021-07-16 Univ Basel Receptores de celulas t restringidos a mr1 para inmunoterapia contra el cancer.
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20220054544A1 (en) * 2018-09-21 2022-02-24 Harpoon Therapeutics, Inc. Conditionally active receptors
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020086647A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
US12325734B2 (en) 2019-01-15 2025-06-10 Altor Bioscience Llc Human immunodeficiency virus-specific T cell receptors
JP7748874B2 (ja) * 2019-03-04 2025-10-03 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体及びその使用方法
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
JP7674278B2 (ja) 2019-07-03 2025-05-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
KR20250070621A (ko) 2022-08-18 2025-05-20 이뮤노코어 리미티드 Mage-a4에 특이적인 t 세포 수용체 융합 단백질
AU2024339041A1 (en) * 2023-09-05 2026-04-16 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
CA2388517A1 (en) 1999-11-16 2001-05-25 The General Hospital Corporation Compositions and methods for regulating tumor-associated antigen expression
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
WO2004087941A1 (en) 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
AU2003268275C1 (en) 2002-08-29 2010-04-01 Cytocure Llc Methods for up-regulating antigen expression in tumors
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8329162B2 (en) * 2006-07-21 2012-12-11 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2010106431A2 (en) 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
WO2011040978A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP3404111A1 (en) * 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen

Also Published As

Publication number Publication date
EP2971045B1 (en) 2019-06-19
EP3404111A1 (en) 2018-11-21
EP2971045A2 (en) 2016-01-20
JP2019080568A (ja) 2019-05-30
US12371470B2 (en) 2025-07-29
JP2016512435A (ja) 2016-04-28
JP6464140B2 (ja) 2019-02-06
US20190002522A1 (en) 2019-01-03
JP6612963B2 (ja) 2019-11-27
WO2014160030A2 (en) 2014-10-02
ES2746240T3 (es) 2020-03-05
US20160024174A1 (en) 2016-01-28
CA2906587C (en) 2023-02-14
WO2014160030A3 (en) 2014-11-27
CA2906587A1 (en) 2014-10-02
EP2971045A4 (en) 2016-10-19
US20220017593A1 (en) 2022-01-20
US10000546B2 (en) 2018-06-19
US11155595B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
DK2971045T3 (da) Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
IL264607A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
IL263466A (en) Anti-cd3 antibodies and methods of use
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
IL254214A0 (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
IL240472A0 (en) Chimeric antigen receptor and methods of use thereof
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3708579T3 (da) Claudin-6-specifikke immunreceptorer og t-celleepitoper
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
PL3226897T3 (pl) Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3292149T3 (da) Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3035955T3 (da) Sammensætning og vaccine til behandling af lungekræft
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK2970456T3 (da) Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse